- It not only consolidates Mubadala’s footprint in the life sciences sector but also positions UAE as a formidable player on global stage.
- Integration of GHH’s assets enhances KELIX bio’s operational capabilities, particularly in cutting-edge biopharmaceutical and intravenous solutions manufacturing.
ABU DHABI: The acquisition of GlobalOne Healthcare Holding’s (GHH) pharmaceutical assets by Mubadala Investment Company PJSC marks a pivotal moment for the life sciences sector in the United Arab Emirates.
Following the successful integration of KELIX bio, a specialty pharmaceutical entity focusing on complex generics in emerging markets, Mubadala’s strategic maneuver to acquire 100 per cent stakes in four GHH assets—namely Bioventure, Bioventure Healthcare, Gulf Inject, and Wellpharma—significantly enhances the nation’s pharmaceutical landscape.
The acquisition aligns seamlessly with Mubadala’s commitment to fostering a robust life sciences ecosystem, thus bolstering the UAE’s position as a global leader in this critical industry.
Dr. Bakheet Al Katheeri, CEO of the UAE Investments Platform at Mubadala, emphasised the swift execution of these strategic acquisitions as a testament to their dedication to developing a knowledge-based economy.
The initiative not only aims to generate substantial socio-economic value for stakeholders but also reinforces the UAE’s ambition to become a centre for innovation and expertise in the life sciences domain.
Competitive edge
The integration of GHH’s assets enhances KELIX bio’s operational capabilities, particularly in cutting-edge biopharmaceutical and intravenous (IV) solutions manufacturing. Each asset contributes unique strengths, ultimately creating a diversified and robust portfolio that is well-positioned for accelerated growth.
Hocine Sidi Said, CEO of KELIX bio, noted that this acquisition provides access to an expanded pipeline of products and technologies, which is crucial for enhancing the company’s competitive edge on a global scale.
Furthermore, the strategic investment aligns with national initiatives such as ‘Operation 300bn’ and ‘Make it in the Emirates’, which are designed to uplift the manufacturing sector and promote self-sufficiency within the economy. By enhancing local capabilities in the pharmaceutical industry, Mubadala’s actions address significant public health challenges, secure drug supplies, and potentially reduce healthcare costs, fostering a healthier populace.
Ismail Ali Abdulla, Head of UAE Clusters at Mubadala, echoed the sentiment of economic diversification and the generation of socio-economic returns. As a responsible investor, Mubadala seeks to nurture future-centric solutions that contribute to GDP growth, job creation, and innovation, thereby shaping the future of communities across the UAE.
